These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 33045130)

  • 1. Population Pharmacokinetics of Remimazolam in Procedural Sedation With Nonhomogeneously Mixed Arterial and Venous Concentrations.
    Zhou J; Curd L; Lohmer LL; Ossig J; Schippers F; Stoehr T; Schmith V
    Clin Transl Sci; 2021 Jan; 14(1):326-334. PubMed ID: 33045130
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A population pharmacodynamic Markov mixed-effects model for determining remimazolam-induced sedation when co-administered with fentanyl in procedural sedation.
    Zhou J; Curd L; Lohmer LRL; Delpratt N; Ossig J; Schippers F; Stoehr T; Schmith VD
    Clin Transl Sci; 2021 Jul; 14(4):1554-1565. PubMed ID: 33768731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part I. Pharmacokinetics and Clinical Pharmacodynamics.
    Schüttler J; Eisenried A; Lerch M; Fechner J; Jeleazcov C; Ihmsen H
    Anesthesiology; 2020 Apr; 132(4):636-651. PubMed ID: 31972655
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part II. Population pharmacokinetic and pharmacodynamic modeling and simulation.
    Wiltshire HR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):284-96. PubMed ID: 22253270
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time-to-Event Modeling for Remimazolam for the Indication of Induction and Maintenance of General Anesthesia.
    Lohmer LL; Schippers F; Petersen KU; Stoehr T; Schmith VD
    J Clin Pharmacol; 2020 Apr; 60(4):505-514. PubMed ID: 31989598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population pharmacokinetic/pharmacodynamic modeling for remimazolam in the induction and maintenance of general anesthesia in healthy subjects and in surgical subjects.
    Zhou J; Leonowens C; Ivaturi VD; Lohmer LL; Curd L; Ossig J; Schippers F; Petersen KU; Stoehr T; Schmith V
    J Clin Anesth; 2020 Nov; 66():109899. PubMed ID: 32585566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychomotor Recovery Following Remimazolam-induced Sedation and the Effectiveness of Flumazenil as an Antidote.
    Chen X; Sang N; Song K; Zhong W; Wang H; Jiang J; Huang Y; Hu P
    Clin Ther; 2020 Apr; 42(4):614-624. PubMed ID: 32178858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A population pharmacokinetic model of remimazolam for general anesthesia and consideration of remimazolam dose in clinical practice.
    Masui K; Stöhr T; Pesic M; Tonai T
    J Anesth; 2022 Aug; 36(4):493-505. PubMed ID: 35708787
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A placebo- and midazolam-controlled phase I single ascending-dose study evaluating the safety, pharmacokinetics, and pharmacodynamics of remimazolam (CNS 7056): Part I. Safety, efficacy, and basic pharmacokinetics.
    Antonik LJ; Goldwater DR; Kilpatrick GJ; Tilbrook GS; Borkett KM
    Anesth Analg; 2012 Aug; 115(2):274-83. PubMed ID: 22190555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and Pharmacodynamics of Remimazolam (CNS 7056) after Continuous Infusion in Healthy Male Volunteers: Part II. Pharmacodynamics of Electroencephalogram Effects.
    Eisenried A; Schüttler J; Lerch M; Ihmsen H; Jeleazcov C
    Anesthesiology; 2020 Apr; 132(4):652-666. PubMed ID: 31972657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Remimazolam Has Low Oral Bioavailability and No Potential for Misuse in Drug-Facilitated Sexual Assaults, with or Without Alcohol: Results from Two Randomised Clinical Trials.
    Pesic M; Stöhr T; Ossig J; Borkett K; Donsbach M; Dao VA; Webster L; Schippers F
    Drugs R D; 2020 Sep; 20(3):267-277. PubMed ID: 32757149
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment.
    Stöhr T; Colin PJ; Ossig J; Pesic M; Borkett K; Winkle P; Struys MMRF; Schippers F
    Br J Anaesth; 2021 Sep; 127(3):415-423. PubMed ID: 34246461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Recirculatory Model for Pharmacokinetics and the Effects on Bispectral Index After Intravenous Infusion of the Sedative and Anesthetic AZD3043 in Healthy Volunteers.
    Björnsson MA; Norberg Å; Kalman S; Simonsson USH
    Anesth Analg; 2015 Oct; 121(4):904-913. PubMed ID: 26097984
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Computer-controlled infusion of intravenous dexmedetomidine hydrochloride in adult human volunteers.
    Dyck JB; Maze M; Haack C; Azarnoff DL; Vuorilehto L; Shafer SL
    Anesthesiology; 1993 May; 78(5):821-8. PubMed ID: 8098191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A phase IIb study comparing the safety and efficacy of remimazolam and midazolam in patients undergoing colonoscopy.
    Pambianco DJ; Borkett KM; Riff DS; Winkle PJ; Schwartz HI; Melson TI; Wilhelm-Ogunbiyi K
    Gastrointest Endosc; 2016 May; 83(5):984-92. PubMed ID: 26363333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetics of doxorubicin: establishment of a NONMEM model for adults and children older than 3 years.
    Kontny NE; Würthwein G; Joachim B; Boddy AV; Krischke M; Fuhr U; Thompson PA; Jörger M; Schellens JH; Hempel G
    Cancer Chemother Pharmacol; 2013 Mar; 71(3):749-63. PubMed ID: 23314734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative population pharmacokinetics of lorazepam and midazolam during long-term continuous infusion in critically ill patients.
    Swart EL; Zuideveld KP; de Jongh J; Danhof M; Thijs LG; Strack van Schijndel RM
    Br J Clin Pharmacol; 2004 Feb; 57(2):135-45. PubMed ID: 14748812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population Pharmacokinetics of Pemetrexed in Adult Non-Small Cell Lung Cancer in Indian Patients.
    Srinivasan M; Chaturvedula A; Fossler MJ; Patil A; Gota V; Prabhash K
    J Clin Pharmacol; 2019 Sep; 59(9):1216-1224. PubMed ID: 30973978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics and pharmacodynamics of intranasal remimazolam-a randomized controlled clinical trial.
    Pesic M; Schippers F; Saunders R; Webster L; Donsbach M; Stoehr T
    Eur J Clin Pharmacol; 2020 Nov; 76(11):1505-1516. PubMed ID: 32886178
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
    Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
    J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.